Japan’s Taisho Considers Entering Chinese Herbal Medicine Market
This article was originally published in PharmAsia News
Japan's Taisho Pharmaceutical plans to expand its range of products by entering the rapidly growing herbal medicine market. The company plans to begin by test-marketing five Chinese herbal medicines in selected regions of Japan, possibly in May. If that test is successful, Taisho plans to market the products nationwide. Chinese herbal medicines have become popular in part for their perceived effect in treating obesity. (Click here for more - a subscription may be required
You may also be interested in...
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.